Jack Wallace
Stock Analyst at Guggenheim
(3.20)
# 1,119
Out of 4,974 analysts
19
Total ratings
57.89%
Success rate
273.2%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $272.93 | -8.77% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $48.41 | -64.88% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $3.38 | +314.81% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $187.68 | +17.22% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $28.13 | +42.20% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $6.98 | +1,332.66% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $25.85 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $272.93
Upside: -8.77%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $48.41
Upside: -64.88%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $3.38
Upside: +314.81%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $187.68
Upside: +17.22%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $28.13
Upside: +42.20%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $6.98
Upside: +1,332.66%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $25.85
Upside: -